SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (357)2/19/2003 5:31:00 PM
From: IRWIN JAMES FRANKEL  Read Replies (1) | Respond to of 508
 
Hi,

The results were as good as could be reasonably expected. 2003 guidance may be disappointing the market on Actimmune sales of $160-$180. Considering this managments inclination to be conservative that guidance is reasuring to me.

However, since I am out - should the market offer me a bargain I may be inclined to reenter. :-)

ij


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News